Review3 Biotech2019
Role of edible mushroom as a potent therapeutics for the diabetes and obesity.
Review in 3 Biotech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 62 citations in OpenAlex.
- A clinical trial on anti-diabetic efficacy of submerged culture medium of Ceriporia lacerata mycelium.BMC complementary medicine and therapies · 2023Trial
- Preparation, Structural Features, Bioactivities, and Food Application of Oyster Mushroom Polysaccharides: A Review.Journal of food science · 2026Review
- Edible and Medicinal Mushrooms as Sources of Bioactive Molecules in Pregnancy: Potential Impact on Preeclampsia and Gestational Diabetes Outcomes.Molecules (Basel, Switzerland) · 2026Review
- Dual Role of Transcription Factors in the Development and Thermogenic Function of Brown Adipose Tissue.International journal of medical sciences · 2026Review
- A review on the role of functional foods and derivatives for diabetes management.Journal of food science and technology · 2025Review
- Comparing the Effects ofClinical diabetes : a publication of the American Diabetes Association · 2025Article
- Bioactive Peptides and Other Immunomodulators of Mushroom Origin.Biomedicines · 2024Review
- LC/MS analysis of mushrooms provided new insights into dietary management of diabetes mellitus in rats.Food science & nutrition · 2023Article
- Exploring Edible Mushrooms for Diabetes: Unveiling Their Role in Prevention and Treatment.Molecules (Basel, Switzerland) · 2023Review
- Evaluation ofDisease markers · 2023Article
- A Review of Development and Utilization for Edible Fungal Polysaccharides: Extraction, Chemical Characteristics, and Bioactivities.Polymers · 2022Review
- Immunostimulatory Effect of Postbiotics Prepared fromPharmaceuticals (Basel, Switzerland) · 2022Article
- Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment.Pharmaceutics · 2022Review
- Transcriptomic analysis of the anti-inflammatory effect ofFrontiers in pharmacology · 2022Article
- Potential Glioprotective Strategies Against Diabetes-Induced Brain Toxicity.Neurotoxicity research · 2021Review
- Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products.Journal of fungi (Basel, Switzerland) · 2020Review
- Effect ofDiabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes and obesity are the most frequently found disease worldwide. Several factors are responsible for obesity, i.e., imbalance in energy expenditure, environmental factors, feeding habit, lifestyle, etc., which can also be responsible for type 2 diabetes mellitus. There are several synthetic drugs available to combat these diseases which have some side effects on sufferers. Therefore, people are shifting towards inexpensive, effective, widely available natural and herbal medicines. Edible mushrooms, which have been used from ancient time to cure these diseases, contain anti-oxidant, fibers, triterpenoids, alkaloid, and other phytochemicals. Comatin, β-glucan, Tremellastin, and Lentinan KS-2 are active chemicals of mushrooms which show great effect on diabetes mellitus and obesity by modulating either cellular function or biochemical pathways. Here, in this review, we have discussed the potential role of edible mushrooms and its biochemicals in control of diabetes and obesity. Using Bioinformatics, we can find the specific targets of theses biochemicals, so that these can be more effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.